India’s IPO Market Faces Litmus Test With 7 Issues in September 2025

Team Startupfeed
2 Min Read

Summary:

  • Amanta Healthcare IPO raises ₹126 Cr in pharma sector boost
  • Vikran Engineering draws marquee investor interest
  • SME IPOs cross ₹265 Cr, showing strong retail appetite

Dalal Street is buzzing as September brings seven IPOs and fifteen listings across sectors including pharma, engineering, technology, and construction. Market experts say this month’s activity could set the tone for the remainder of 2025.

Pharma’s Strong Start

Amanta Healthcare kicked off the action by raising ₹126 crore, reinforcing pharma’s position as a sector investors continue to favor in the post-pandemic growth cycle.

Engineering in Spotlight

Vikran Engineering has become a key talking point, thanks to interest from marquee investors. With India’s infrastructure and manufacturing focus rising, engineering firms are attracting heightened attention.

SME Segment Picks Up Pace

The SME IPO market is contributing significantly, with over ₹265 crore raised this month alone. This reflects increasing retail participation and confidence in smaller, high-growth businesses.

What’s at Stake

With multiple listings crowded into September, the performance of these IPOs will serve as a litmus test for India’s market appetite. A strong showing could pave the way for bigger issues ahead, while weaker debuts may temper investor enthusiasm.

September’s IPO season is more than numbers — it’s about gauging investor confidence. The real question: Which IPOs are worth betting on?

Share This Article